Drug design by virtual reality - how close are we?

Abstract

The publicity surrounding virtual reality (VR) has left the public with images of researchers projected into the heart of molecules, sculpting cures for AIDS and cancer with their bare hands. Even if the technology was capable of such feats, is this a useful path to follow or does it miss the point entirely, like the VR promises of holidays without leaving home? According to researchers from Glaxo, the University of York, and the VR company, Division, all based in the UK, VR does have significant potential.